)
)
)
Derisking Commercialization Plans to Attract Investment
As biotech funding dynamics evolve, investors are seeking capital models that reward commercial discipline and strategic partnership. Traditional venture pathways are giving way to hybrid approaches — royalty-backed financing, milestone-linked investments, and collaborative commercialization partnerships that preserve capital and accelerate growth. This discussion will examine how biotech companies are navigating this new environment. What defines an investable biotech in 2026? What is the new biotech capital stack? How are partnerships reshaping valuation, risk and ROI?
Moderator
Speakers
.png)
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
